Meta-Analysis of Efficacy and Adverse Events of Erlotinib-Based Targeted Therapies for Advanced/Metastatic Non-Small Cell Lung Cancer

Oncotarget - United States
doi 10.18632/oncotarget.19735
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Impact Journals, LLC

Related search

Comparative Efficacy of Targeted Therapies in Patients With Non-Small Cell Lung Cancer: A Network Meta-Analysis of Clinical Trials

Journal of Clinical Medicine
2020English

Comparative Efficacy of Treatments for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (Nsclc): A Network Meta-Analysis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Prm70 - Non-Small Cell Lung Cancer Market Analysis for Targeted Therapies in Turkey

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

A Systematic Review of the Cost-Effectiveness of Targeted Therapies for Metastatic Non-Small Cell Lung Cancer (NSCLC)

BMC Pulmonary Medicine
PulmonaryRespiratory Medicine
2014English

Determinants of Survival in Advanced Non–Small-Cell Lung Cancer in the Era of Targeted Therapies

Clinical Lung Cancer
Cancer ResearchOncologyRespiratory MedicinePulmonary
2013English

The Efficacy of Erlotinib as Molecularly Targeted Maintenance Therapy in Advanced Non-Small-Cell Lung Cancer (NSCLC): Case Reports in Western Iran

Journal of Solid Tumors
Cancer ResearchOncologyRadiologyNuclear MedicineImaging
2014English

A Tabulated Summary of Targeted and Biologic Therapies for Non–Small-Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2012English

Targeted Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer

Chest
CardiologyCritical CareCardiovascular MedicineIntensive Care MedicinePulmonaryRespiratory Medicine
2005English

Gefitinib in Pretreated Advanced Non-Small Cell Lung Cancer (Nsclc): Analysis of Efficacy

Research in Oncology
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy